Akero Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell AKRO and other ETFs, options, and stocks.About AKRO
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body.
CEOAndrew Cheng
CEOAndrew Cheng
Employees63
Employees63
HeadquartersSouth San Francisco, California
HeadquartersSouth San Francisco, California
Founded2017
Founded2017
Employees63
Employees63
AKRO Key Statistics
Market cap4.09B
Market cap4.09B
Price-Earnings ratio-13.72
Price-Earnings ratio-13.72
Dividend yield—
Dividend yield—
Average volume2.00M
Average volume2.00M
High today—
High today—
Low today—
Low today—
Open price$52.76
Open price$52.76
Volume0.00
Volume0.00
52 Week high$58.40
52 Week high$58.40
52 Week low$21.02
52 Week low$21.02
Analyst ratings
100%
of 10 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own AKRO. This list is generated using Robinhood data, and it’s not a recommendation.